spacer
home > ebr > winter 2002 > dealing with the pitfalls of intellectual property co-ownership in international biopharmaceutical r&d joint ventures
PUBLICATIONS
European Biopharmaceutical Review

Dealing with the Pitfalls of Intellectual Property Co-Ownership in International Biopharmaceutical R&D Joint Ventures

Biopharmaceutical companies increasingly join forces to research and develop new drugs and therapies. Among the many reasons for entering into collaborative R&D agreements are the sharing of risk and cost, enhanced access to complementary resources of competent research personnel, financial resources and background intellectual property (IP), as well as marketing considerations such as access to new markets. Underpinning these specific motivations is the overall objective of increasing creativity through interaction in R&D. From a legal perspective, the goal of R&D joint ventures is to create and exploit new intellectual property rights (IPRs), particularly patents (1).In this respect, ownership of IPRs often proves to be one of the most sensitive issues if it is not properly addressed at the outset of the venture. The risk of inadequate allocation of IPRs resulting from unintended joint ownership of the IPRs is indeed that these rights may not be properly used by the parties and may not be enforced against third party infringers, if the parties to the joint R&D project do not consent on the course of action to be adopted.


Read full article from PDF >>

Rate this article You must be a member of the site to make a vote.  
Average rating:
0
     

There are no comments in regards to this article.

spacer
By Thierry Calame, Attorney at Law with Lenz & Staehelin Thierry Calame is an Attorney at Law specialising in intellectual property law with Lenz & Staehelin. He represents clients in patent litigation and other IP-related litigation and advises on a wide range of IP- and technology-related commercial matters and licensing. He has a particular focus on clients in the pharmaceutical and biotechnology sectors.
Thierry holds a degree from the Swiss Federal Institute of Technology (ETH) in Chemistry and a Law degree from the University of St Gallen, Switzerland.

spacer
Thierry Calame
spacer
spacer
Print this page
Send to a friend
Privacy statement
News and Press Releases

Three-tiered, mobile-app driven program tracks individuals’ physical and psychological symptoms from COVID-19

RALEIGH, N.C., March 20, 2020 (GLOBE NEWSWIRE) -- PRA Health Sciences announced today the commercial availability of the COVID-19 Monitoring Program, a mobile app-driven, tiered initiative that allows employers, payers, providers and health systems to track the health and wellbeing of individuals who may be asymptomatic, exposed or diagnosed with COVID-19 during the pandemic.
More info >>

White Papers

What is process characterization?

EXPUTEC

Process characterization is an essential step in the commercialization of a new (biological) drug. For drug product commercialization, manufacturers must validate the drug’s manufacturing process. This ensures that the manufacturing process delivers consistently a quality product and that the patient is not at risk.
More info >>

 
Industry Events

Formulation and Drug Delivery Series UK

8-9 July 2020, Oxford Global

This event brings together leading formulation, drug delivery and biologics manufacturing experts from around the world across two days. The panel of prominent industry leaders and world-leading scientists will share the latest case studies, innovative developments for novel therapeutic products and strategies for drug development.
More info >>

 

 

©2000-2011 Samedan Ltd.
Add to favourites

Print this page

Send to a friend
Privacy statement